New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 30, 2019 - Bayer announced the FDA approval of Nubeqa (darolutamide), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
Download PDF
Return to publications
